Multiple Myeloma Drug Therapy: Considerations on Effectiveness and Safety-Reference-Cited by-同舟云学术

Multiple Myeloma Drug Therapy: Considerations on Effectiveness and Safety

Published:2024 Issue: Volume: Page:
ISSN:2731-4561
Container-title:Interdisciplinary Cancer Research
language:
Short-container-title:

Author:

Menezes de Pádua Cristiane A.^ORCID,Drummond Paula L. M.^ORCID,Malta Jéssica S.^ORCID,Silveira Lívia P.^ORCID,Costa Iwyson H. F.^ORCID,Reis Adriano M. M.^ORCID

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/16833_2024_252

Reference140 articles.

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365

2. Abramson HN (2023) Recent advances in the applications of small molecules in the treatment of multiple myeloma. Int J Mol Sci 24(3). https://doi.org/10.3390/ijms24032645

3. AGS (2023) By the American Geriatrics Society 2023 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 71(7):2052–2081. https://doi.org/10.1111/jgs.18372

4. Anderson SM, Beck B, Sterud S, Lockhorst R, Ngorsuraches S (2019) Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. J Oncol Pharm Pract 25(4):806–812. https://doi.org/10.1177/1078155218758500

5. Bahk JH, Jo WL, Kwon SY, Park HC, Lim YW (2023) Weight-based bisphosphonate administration for multiple myeloma patients and the risks of skeletal complications. J Clin Med 12(4). https://doi.org/10.3390/jcm12041637